MAPK1IP1L

Across TCGA pan-cancer cohorts, MAPK1IP1L mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MAPK1IP1L data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAPK1IP1L mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAPK1IP1L expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where MAPK1IP1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.843	0.538	.007	18	view →
PDAC	OS	Quartile	All	0.631	0.445	.014	5	view →
HNSC	DFS	Median	All	0.338	0.777	.039	4	view →
LSCC	OS	Median	All	0.930	0.833	.018	4	view →
GBM	DFS	Median	All	0.258	0.480	.018	2	view →
LUAD	OS	Tertile	All	0.608	0.914	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MAPK1IP1L–CCRCC (DFS)

Open the CCRCC breakdown →